Prescriber Scope of Practice for ADHD in New York

If you’re a psychiatrist or psychiatric nurse practitioner considering telehealth for ADHD treatment, you’ve probably asked: Can I legally prescribe Adderall or other stimulants through video visits? It’s not a simple yes or no—the answer depends on federal DEA rules, your state’s laws, and your provider type.

The good news: As of 2026, telehealth prescribing of ADHD medications is still fully legal under federal temporary rules extended through December 31, 2026. But the landscape is shifting. The DEA is finalizing permanent regulations that will introduce new requirements, and each state has its own quirks—especially for nurse practitioners.

This guide cuts through the confusion. We’ll explain the current federal flexibilities, what’s changing, state-specific rules for California, Texas, Florida, New York, Pennsylvania, and Illinois, and how scope of practice affects NPs vs. psychiatrists. Whether you’re already practicing telehealth or exploring it, you’ll know exactly where you stand legally.

Federal Rules: Where Things Stand Right Now (2026)

The Ryan Haight Act and COVID-Era Waivers

Under normal circumstances, the Ryan Haight Online Pharmacy Consumer Protection Act requires an in-person medical exam before prescribing any Schedule II controlled substance—including ADHD medications like Adderall, Ritalin, or Vyvanse. Before March 2020, this meant you couldn’t start a patient on stimulants after just a video consult.

COVID changed everything. In March 2020, the DEA waived the in-person requirement, allowing providers to prescribe Schedule II–V controlled substances via telehealth if the prescription was issued for a legitimate medical purpose and the encounter used real-time audio-visual communication. This waiver enabled the telehealth ADHD care boom we’ve seen over the past few years.

Current Status (Through End of 2026): The DEA and HHS have extended these flexibilities four times. The latest extension runs through December 31, 2026, meaning you can continue prescribing ADHD medications via telehealth without an initial in-person visit, as long as you:

• Conduct a proper evaluation via live video (audio-only doesn’t cut it for stimulants)
• Follow standard prescribing protocols (legitimate diagnosis, appropriate dosing, documentation)
• Use electronic prescribing for Schedule II medications
• Check your state’s Prescription Drug Monitoring Program (PDMP) as required

This extension gives providers breathing room while the DEA finalizes permanent rules. But make no mistake—the temporary nature of this flexibility creates uncertainty for 2027 and beyond.

What’s Coming: DEA’s Permanent Telemedicine Rules

The DEA received over 38,000 public comments on its initial proposed rules and has since developed three new regulations announced in January 2025. Here’s what matters for ADHD providers:

1. Telemedicine Special Registration
The DEA is creating a special registration pathway that will allow providers to prescribe controlled substances via telehealth without an in-person exam. To qualify, you’ll need to:

• Obtain a ‘Telemedicine Special Registration’ in addition to your standard DEA number
• Conduct mandatory nationwide PDMP checks (the DEA plans to establish a national data hub)
• Verify patient identity during audio-video consultations
• Comply with additional safeguards still being finalized

For ADHD-focused telehealth providers, this registration will likely become essential once the temporary blanket waiver expires in 2027.

2. Established Patient Exception
If a patient has been seen in person at least once by you or another provider in your practice, the new telemedicine rules won’t apply. You can continue treating via telehealth freely. This matters for hybrid practices or situations where patients move and want to continue care remotely.

3. Platform Registration Requirements
For the first time, the DEA will require telehealth platforms (companies that facilitate virtual visits) to register with the agency. This adds corporate-level oversight to prevent ‘pill mill’ behavior and means platforms like Klarity will need to maintain DEA compliance—good news for providers who want to work with legitimate organizations.

Timeline: The DEA hasn’t published final rule text yet (as of February 2026), but implementation is expected before the current extension expires at year-end. Providers should plan to obtain the special registration in late 2026 or early 2027 to avoid disruptions.

Bottom line: Federal law currently allows telehealth ADHD prescribing, and permanent rules will likely preserve that access with additional safeguards. Stay tuned for updates as the DEA finalizes regulations.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Breakdown: Where You Can Prescribe ADHD Meds via Telehealth

Federal rules set the floor, but states can add their own requirements—or in some cases, make things easier. Here’s what you need to know for the six states with the highest demand for ADHD telehealth services.

California: Telehealth-Friendly with NP Independence on the Horizon

Can you prescribe ADHD meds via telehealth? Yes, with no state-imposed restrictions beyond federal law.

Key Points:

• No in-person exam required by California law. The state explicitly allows telehealth encounters to satisfy prescribing standards for controlled substances.
• PDMP checks mandatory: You must query California’s CURES database before the initial prescription and at least every 4 months for ongoing Schedule II stimulant therapy.
• E-prescribing required for all controlled substances.

Licensure: You need a full California license—the state isn’t part of the Interstate Medical Licensure Compact (IMLC), and there’s no special telehealth registration for out-of-state providers.

For Psychiatrists (MD/DO): Full prescribing authority with no special limitations. Standard practice.

For PMHNPs: California is transitioning to Full Practice Authority (FPA) for nurse practitioners. Under AB 890 (passed 2020), NPs who complete 3 years or 4,600 hours of practice under physician supervision can apply for independent practice status. By 2026, experienced PMHNPs in California can prescribe ADHD medications without physician oversight. New graduates still need a supervising physician initially, but this opens up as they gain experience.

What this means: California’s regulatory environment is becoming increasingly favorable for telehealth ADHD care, especially for nurse practitioners. The CURES check is the main compliance burden—make it routine before every stimulant prescription.

Texas: Physicians Only for Schedule II Stimulants

Can you prescribe ADHD meds via telehealth? Yes for psychiatrists; no for nurse practitioners.

Key Points:

• Texas law permits telehealth for mental health treatment, including ADHD.
• Critical restriction: Texas prohibits nurse practitioners and physician assistants from prescribing Schedule II controlled substances in outpatient settings. The only exceptions are inpatient hospital orders, hospice care, or ER emergency medications.
• This means only physicians (MD/DO) can prescribe Adderall, Ritalin, Concerta, or other stimulants for outpatient ADHD treatment in Texas—including via telehealth.

For Psychiatrists: Full prescribing authority via telehealth. You must use video for the evaluation (standard of care), and electronic prescribing is mandatory for all controlled substances in Texas (as of 2021). The Texas PMP doesn’t legally require checking for stimulants (it mandates checks for opioids, benzos, barbiturates, and carisoprodol), but best practice is to review it anyway.

For PMHNPs: You can evaluate and diagnose ADHD patients via telehealth, but you cannot prescribe stimulants. You must work with a collaborating physician who writes the actual prescription. Texas NPs can prescribe Schedule III–V medications under physician delegation, but Schedule II is off-limits for outpatient care.

Licensure: Texas is an IMLC state for physicians, so out-of-state MDs/DOs can expedite licensure. NPs need a full Texas license and must establish a physician collaboration agreement.

What this means: If you’re building an ADHD telehealth practice in Texas, plan on having psychiatrists handle all stimulant prescriptions. NPs can manage the clinical side but need physician backup for meds. This is the most restrictive of the six states we’re covering.

Florida: Explicit Exception for Psychiatric Disorders

Can you prescribe ADHD meds via telehealth? Yes—Florida law explicitly permits it.

Key Points:

• Florida Statute §456.47 generally prohibits prescribing Schedule II controlled substances via telehealth, except for treatment of psychiatric disorders, inpatient care, hospice, or nursing facility residents.
• ADHD qualifies as a psychiatric disorder, so prescribing stimulants via telehealth is explicitly legal in Florida.
• This carve-out makes Florida one of the clearer states for ADHD telehealth—the law anticipated mental health treatment needs.

For Psychiatrists: Straightforward. You can treat Florida ADHD patients via telehealth with a Florida license or by registering as an out-of-state telehealth provider (Florida allows this—you register with the Department of Health without getting a full license, though you still need a Florida DEA registration). You must check Florida’s PDMP (E-FORCSE) before prescribing controlled substances for patients 16 and older.

For PMHNPs: Florida requires nurse practitioners to practice under a protocol agreement with a supervising physician (a psychiatrist for mental health prescribing). However, Florida law exempts ‘psychiatric nurses’ (PMHNPs with advanced psychiatric training and 2+ years experience) from the usual 7-day limit on Schedule II prescriptions. A qualified PMHNP can prescribe stimulants for ongoing treatment without day-supply restrictions—but the supervising psychiatrist relationship must be documented. Florida did not include psychiatric NPs in its 2020 independent practice law, so supervision remains mandatory.

Licensure: Florida isn’t an IMLC state, but the out-of-state telehealth registration option is valuable. You can practice in Florida from another state if you meet the criteria (active unrestricted license elsewhere, clean record, malpractice insurance) and register. This registration allows you to prescribe ADHD meds under the psychiatric exception.

What this means: Florida’s clear statutory language removes ambiguity. Just ensure you document that treatment is for a psychiatric disorder (ADHD), stay current with E-FORCSE checks, and if you’re an NP, maintain your physician protocol agreement.

New York: Recently Updated to Align with Federal Flexibility

Can you prescribe ADHD meds via telehealth? Yes, explicitly as of May 2025.

Key Points:

• New York updated its regulations in May 2025 to formally allow controlled substance prescribing via telehealth in line with federal DEA rules. The state had an old rule mirroring Ryan Haight, but now it permits telehealth prescribing as long as it’s consistent with federal law.
• PMP checks mandatory: You must check New York’s I-STOP/PMP registry before prescribing any Schedule II, III, or IV controlled substance—that includes every stimulant prescription.
• E-prescribing required for all controlled substances (New York has mandated this since 2016).
• Unique benefit: New York allows up to a 90-day supply of stimulants for ADHD if you indicate it’s for ‘minimal brain dysfunction’ (the older diagnostic term for ADHD) by using prescription code ‘B.’ This reduces refill hassle for stable patients.

For Psychiatrists: Full authority to prescribe via telehealth. New York’s 2025 update removed any state-level barrier, so you’re governed by federal rules. Document your evaluations thoroughly and run the PMP check every time.

For PMHNPs: New York is one of the better states for nurse practitioners. Under the NP Modernization Act of 2015, NPs with more than 3,600 hours of practice can practice independently without a written collaborative agreement (though they must have a ‘collaborative relationship’ with a physician for consultation, not direct supervision). New York PMHNPs can prescribe Schedule II–V controlled substances with their own DEA registration. There are no quantity limits specific to NPs for stimulants—you can prescribe the same as physicians, including the 90-day supply option for ADHD.

Licensure: New York isn’t part of IMLC, and there’s no special telehealth license. You need a full NY medical or nursing license. NPs also need a NYS narcotic prescribing number in addition to DEA registration.

What this means: New York’s May 2025 regulatory update gives providers confidence that state law won’t contradict federal telehealth allowances. The PMP check is non-negotiable—build it into your workflow before every stimulant prescription. The 90-day supply provision is a practical advantage for telehealth continuity of care.

Pennsylvania: Permissive but NPs Have Limits

Can you prescribe ADHD meds via telehealth? Yes, though nurse practitioners face prescribing restrictions.

Key Points:

• Pennsylvania has no state law prohibiting telehealth prescribing of controlled substances—the state defers to federal regulations.
• Medical boards confirm that a valid patient-provider relationship can be established via telemedicine and prescribing is acceptable if standard of care is met.
• PDMP checks required: Pennsylvania law mandates checking the state PDMP before prescribing opioids or benzodiazepines each time, and before the initial prescription of any other controlled substance. Best practice for ADHD: check the PDMP for every stimulant prescription.
• E-prescribing mandatory for controlled substances (effective 2019 under Act 96).

For Psychiatrists: No special restrictions. You can prescribe ADHD medications via telehealth following federal guidelines and documenting proper evaluations. Pennsylvania is an IMLC state (joined 2022), so out-of-state physicians can expedite licensure.

For PMHNPs (CRNPs): Pennsylvania is a restricted practice state requiring nurse practitioners to have a collaborative agreement with a physician. The key limitation: CRNPs can prescribe Schedule II controlled substances for up to a 30-day supply only. Any continuation beyond 30 days requires the collaborating physician’s approval. This means for ongoing ADHD treatment, you’ll need monthly check-ins with your supervising psychiatrist (or at minimum, documentation that they’ve reviewed and approved continuation). For Schedule III or IV medications, Pennsylvania allows up to 90-day supplies.

Licensure: Pennsylvania requires a full state license for practice. The NP must also have a collaborative agreement on file with the Board of Nursing.

What this means: If you’re a PMHNP in Pennsylvania doing telehealth ADHD care, plan your workflow around the 30-day limit—either schedule monthly physician consultations or ensure your collaborating psychiatrist reviews cases regularly. It’s not as restrictive as Texas (you can still prescribe), but it requires ongoing physician involvement. For psychiatrists, Pennsylvania is straightforward.

Illinois: Full Practice Authority Available for Experienced NPs

Can you prescribe ADHD meds via telehealth? Yes, and Illinois offers a path to NP independence.

Key Points:

• Illinois permits telehealth for all medical services with parity requirements. There’s no state prohibition on controlled substance prescribing via telemedicine.
• Illinois Controlled Substance License required: Any provider prescribing controlled substances in Illinois must have a state CS license in addition to their DEA registration (apply through IL DFPR).
• PDMP checks: Illinois law mandates documenting a PMP check for opioid prescriptions and initial benzodiazepine prescriptions. While not explicitly required for stimulants, checking the Illinois PMP (AWARxE) is recommended as best practice.

For Psychiatrists: Full prescribing authority via telehealth. Ensure you have your Illinois medical license and Illinois controlled substance license. Illinois is an IMLC state for physicians.

For PMHNPs: Illinois offers two tiers of practice:

1. Under Collaboration: An APRN without Full Practice Authority must have a written collaborative agreement with a physician. For Schedule II stimulants, the NP can prescribe an initial 30-day supply, but any continuation beyond 30 days requires the collaborating physician’s approval. The physician must also review the NP’s Schedule II prescribing monthly.

2. Full Practice Authority (FPA): APRNs who complete 4,000 hours of clinical practice under collaboration and 250 hours of continuing education can apply for independent practice. FPA-certified APRNs can prescribe Schedule II–V controlled substances without physician collaboration, with one caveat: If prescribing Schedule II narcotic drugs (opioids) or benzodiazepines, they must maintain a ‘consultation relationship’ with a physician. However, this consultation requirement does not apply to Schedule II non-narcotic substances—which includes stimulants for ADHD. Therefore, an Illinois FPA-certified PMHNP can prescribe Adderall, Ritalin, etc., independently via telehealth without needing physician oversight or monthly consultations.

Licensure: Illinois requires a state license for both medicine and nursing. Out-of-state providers need to obtain Illinois licensure (IMLC available for MDs). APRNs need an Illinois APRN license plus Illinois controlled substance license.

What this means: Illinois is favorable for experienced PMHNPs who’ve achieved FPA—they have the same prescribing freedom as psychiatrists for ADHD medications. If you’re a newer NP under collaboration, expect the 30-day limit and monthly physician review (similar to PA). For psychiatrists, Illinois is straightforward.

Note: Illinois also has ‘Prescribing Psychologists’ (clinical psychologists with advanced training who can prescribe psychotropic medications under physician collaboration), but they are prohibited from prescribing Schedule II substances, so ADHD medications are off-limits for them.

Quick Comparison Table: State Telehealth Rules for ADHD Prescribing

What This Means for Your Practice Economics

The regulatory landscape directly impacts your ability to acquire and treat ADHD patients profitably via telehealth. Here’s the business reality:

DIY Patient Acquisition is Expensive and Uncertain
If you try to market your telehealth ADHD practice yourself, you’re looking at:

• SEO: 6–12 months of consistent investment (content, website optimization, backlinks) before you see meaningful organic traffic. Most solo providers don’t have the expertise or patience.
• Google Ads: Mental health keywords cost $15–40+ per click. Conversion rates vary wildly. Realistically, you might spend $200–400+ per booked patient after accounting for clicks that don’t convert, no-shows from cold leads, and ongoing optimization costs.
• Directory Listings: Psychology Today, Zocdoc, and similar platforms charge monthly fees ($100–300+) and you’re competing with hundreds of other providers on the same page. Zocdoc charges per booking ($35–100+ each), and monthly costs add up quickly.
• All-in costs: When you factor in agency fees, ad testing, staff time to handle and qualify leads, no-show rates, and failed campaigns, acquiring a qualified psychiatric patient typically costs $200–500+—if not more.

For most providers, especially those starting out or scaling up, spending $3,000–5,000/month on marketing with uncertain results is a gamble.

The Platform Economics Advantage
Klarity Health uses a pay-per-appointment model—similar to Zocdoc but designed specifically for psychiatric care. Instead of upfront marketing spend or monthly subscriptions, you pay a standard listing fee per new patient lead that books with you. Key advantages:

• No upfront marketing spend: Zero risk on ads that don’t convert
• Pre-qualified patients: Matched to your specialty (ADHD), availability, and accepted insurance
• No wasted ad spend: You only pay when a qualified patient actually books and shows up
• Built-in telehealth infrastructure: No separate platform costs, EHR integration, or billing headaches
• Both insurance and cash-pay patient flow: Diversified revenue streams
• You control your schedule: Scale up or down without fixed costs

ROI Comparison:
Instead of gambling $5,000/month on Google Ads hoping for 10–15 new patients (with no guarantee), you pay only when patients book. That’s guaranteed ROI versus uncertain marketing spend. For providers who value financial predictability and want to focus on clinical care rather than marketing execution, the platform model removes the risk entirely.

Can DIY marketing eventually be cost-effective? Sure—if you have the budget, expertise, and patience. But for most psychiatrists and PMHNPs, especially those navigating the complex regulations outlined above, a platform that handles patient acquisition while ensuring compliance is simply smarter business.

Psychiatrist vs. Nurse Practitioner: Scope of Practice Summary

Understanding the regulatory difference between psychiatrists and PMHNPs matters for building your practice:

Psychiatrists (MD/DO):

• Full prescribing authority in all 50 states for any medication, including Schedule II stimulants
• No state-imposed quantity limits or supervision requirements
• Must comply with state PDMP, e-prescribing, and telehealth evaluation standards, but otherwise unrestricted
• Typically easier to obtain multi-state licenses via IMLC (available in 40+ states)

Psychiatric Nurse Practitioners (PMHNPs):

• Can diagnose and treat ADHD in all 50 states
• Can prescribe Schedule II stimulants in most states, but scope is state-dependent:
• Texas: Cannot prescribe Schedule II to outpatients (physician required)
• Pennsylvania: 30-day limit on Schedule II; physician approval needed for continuation
• Illinois (under collaboration): 30-day limit; physician approval and monthly review required
• Illinois (FPA): Full independence for ADHD prescribing once certified
• Florida: Physician supervision required; psychiatric NPs can prescribe full ADHD treatment under protocol
• California: Transitioning to independence by 2026 for experienced NPs
• New York: Experienced NPs (3,600+ hours) practice independently with no limits
• Many states require physician collaboration agreements, which adds administrative complexity
• Some states limit initial Schedule II prescriptions to 30 days or less

What This Means:
If you’re a psychiatrist, regulatory compliance is straightforward—focus on licensure, PDMP checks, and federal DEA rules. If you’re a PMHNP, understand your state’s requirements thoroughly. In restrictive states like Texas, you’ll need a physician collaborator to handle stimulant prescriptions. In states moving toward FPA (CA, NY, IL), experienced NPs have nearly the same freedom as physicians.

For platforms like Klarity: we ensure the right provider type is matched to each state’s regulations, so you’re never put in a non-compliant situation.

FAQs: Telehealth ADHD Prescribing

Can I prescribe Adderall via telehealth without ever seeing the patient in person?
Yes, through December 31, 2026 under federal rules. After that, you’ll likely need a DEA Telemedicine Special Registration to continue prescribing to new patients without an in-person exam. If a patient has been seen in person once (by you or a colleague in your practice), you can continue via telehealth indefinitely.

Do I need a separate DEA registration for telehealth prescribing?
Not currently (through 2026). Under the upcoming permanent rules, you’ll need a Telemedicine Special Registration in addition to your standard DEA number if you want to prescribe controlled substances to new patients without an in-person visit. Details are still being finalized.

What’s the difference between prescribing ADHD meds and other psychiatric medications via telehealth?
ADHD medications (stimulants) are Schedule II controlled substances, so they fall under stricter DEA rules. Medications like SSRIs (for depression) or non-controlled anxiety meds can be prescribed via telehealth without any special federal restrictions. ADHD treatment requires more regulatory attention due to the controlled substance status.

Can I use audio-only (phone call) for ADHD evaluations and prescribing?
No. Federal guidance requires real-time, two-way audio-visual communication (video) for prescribing controlled substances via telehealth. Audio-only is not sufficient for initial ADHD evaluations or stimulant prescriptions under current rules. Some states allow audio-only for established patients on non-controlled meds, but not for Schedule II substances.

Do I need to check the PDMP every time I prescribe a stimulant?
It depends on your state:

• California: Yes, at initial prescription and every 4 months
• New York: Yes, every time for Schedule II
• Florida: Yes, before prescribing for patients 16+
• Texas: Not legally required for stimulants (required for opioids/benzos), but highly recommended
• Pennsylvania: Required at initial prescription and for ongoing opioid/benzo therapy (best practice: check for stimulants too)
• Illinois: Required for opioids and initial benzos; best practice for stimulants

Even if not legally mandated in your state, checking the PDMP every time protects you from liability and helps identify patients who may be getting medications from multiple providers.

Can nurse practitioners prescribe ADHD medications in all states?
No. PMHNPs can diagnose and treat ADHD in all 50 states, but prescribing Schedule II stimulants depends on state law:

• Prohibited: Texas (outpatient Schedule II ban for NPs)
• Restricted: Pennsylvania and Illinois (under collaboration) require 30-day limits and physician approval for continuation
• Supervised: Florida requires physician protocol agreements for PMHNPs
• Independent (or transitioning): California (by 2026), New York (3,600+ hours), Illinois (FPA certified)

If you’re an NP practicing in multiple states, know each state’s specific rules.

What happens after December 31, 2026 when the current federal extension expires?
The DEA is expected to finalize permanent telehealth prescribing rules before the deadline. These rules will likely include the Telemedicine Special Registration pathway, mandatory PDMP checks, and patient identity verification requirements. Providers should plan to obtain the special registration in late 2026 to avoid disruption. We’ll update our guidance as soon as the final rules are published.

Do I need malpractice insurance that covers telehealth?
Yes. Most malpractice carriers now include telehealth coverage, but verify your policy explicitly covers virtual prescribing of controlled substances. Some older policies may have exclusions. If you’re practicing in multiple states, ensure your coverage extends to those jurisdictions.

Can I treat pediatric ADHD patients via telehealth?
Yes, as long as you follow the same standards as adult treatment. Key considerations:

• Obtain parent/guardian consent (document it)
• Some states have specific telehealth consent requirements for minors
• Clinical best practice may include having the parent present during initial evaluations
• Dosing and diagnosis criteria for pediatric ADHD differ from adults—ensure you’re comfortable with pediatric psychiatric care or limit your practice to adults

What documentation do I need for telehealth ADHD evaluations?
Document as you would for in-person visits:

• Date, time, and duration of telehealth encounter
• Patient consent for telehealth treatment
• Complete psychiatric history and ADHD symptom assessment (DSM-5 criteria)
• PDMP check results and date
• Clinical rationale for prescribing stimulant medication
• Medication name, dose, quantity, and duration
• Follow-up plan

Some states explicitly require noting that the encounter was via telehealth in your medical records. Robust documentation protects you legally and clinically.

Next Steps: Join Klarity’s Provider Network

If you’re a psychiatrist or psychiatric nurse practitioner looking to treat ADHD patients via telehealth—without the headache of patient acquisition, compliance tracking, or platform costs—Klarity Health offers a better path.

Why providers choose Klarity:

• Pre-qualified ADHD patient leads matched to your availability and specialty
• Pay-per-appointment model—no upfront marketing spend or monthly fees
• Compliance support across all six priority states (CA, TX, FL, NY, PA, IL)
• Built-in telehealth infrastructure with EHR, e-prescribing, and billing integrated
• Both insurance and cash-pay patients for diversified revenue
• Flexibility—control your schedule, scale up or down as needed

We handle the complexity of state-specific regulations, ensure you’re matched with patients you’re legally allowed to treat, and provide the infrastructure to make telehealth ADHD care profitable and sustainable.

Ready to grow your practice? Explore Klarity’s provider network or reach out to learn how we support psychiatrists and PMHNPs building telehealth ADHD practices in 2026 and beyond.

Citations and Sources

All regulatory information in this guide has been verified against official government sources and legal statutes as of February 2026. Key sources include:

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026)
   www.hhs.gov/press-room/dea-telemedicine-extension-2026.html
   Official announcement of fourth extension of telehealth controlled substance prescribing flexibilities through December 31, 2026.

2. Healthcare Dive – ‘DEA, HHS extend telehealth controlled substance prescribing flexibilities for fourth time’ (January 5, 2026)
   www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735
   Industry news summary confirming Schedule II–V coverage and timeline context.

3. DEA Press Release – ‘DEA Announces Three New Telemedicine Rules’ (January 16, 2025)
   www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access
   Official DEA announcement of proposed permanent telemedicine regulations, including special registration and PDMP requirements.

4. New York State Department of Health – Bureau of Narcotic Enforcement Guidance (May 21, 2025)
   www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth
   Official New York state guidance aligning state law with federal telehealth flexibilities for controlled substance prescribing.

5. Florida Statutes §456.47 – Telehealth Law (Current through 2025)
   www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html
   Primary legal text establishing Florida’s psychiatric disorder exception for Schedule II telehealth prescribing.

This guide reflects the regulatory landscape as of February 10, 2026. Federal and state telehealth rules continue to evolve. Providers should verify current requirements in their jurisdiction and consult legal counsel when necessary.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care